Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
INM

INM - InMed Pharmaceuticals Inc. Stock Price, Fair Value and News

$1.08+0.01 (+0.93%)
Market Closed

72/100

INM

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

72/100

INM

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.56

Target 3M

$1.21

Target 6M

$1.32

INM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

INM Price Action

Last 7 days

-6.1%

Last 30 days

-9.2%

Last 90 days

-41.6%

Trailing 12 Months

-71.5%

INM RSI Chart

INM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

INM Valuation

Market Cap

3.0M

Price/Earnings (Trailing)

-0.37

Price/Sales (Trailing)

0.63

EV/EBITDA

0.79

Price/Free Cashflow

-0.4

INM Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.56

Target 3M

$1.21

Target 6M

$1.32

INM Fundamentals

INM Revenue

Revenue (TTM)

4.8M

Rev. Growth (Yr)

-11.43%

Rev. Growth (Qtr)

-14.15%

INM Earnings

Earnings (TTM)

-8.2M

Earnings Growth (Yr)

-2.92%

Earnings Growth (Qtr)

3.43%

INM Profitability

Operating Margin

33.69%

EBT Margin

-171.13%

Return on Equity

-70.84%

Return on Assets

-61.46%

Free Cashflow Yield

-249.22%

INM Investor Care

Shares Dilution (1Y)

319.94%

Diluted EPS (TTM)

-6.27

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20254.9M4.9M4.8M0
20245.6M4.6M5.0M4.8M
20233.4M4.1M4.7M5.5M
202201.1M1.9M2.6M
20210000
Get all data in R, Python etc through our Historical Stock Data APIs

About InMed Pharmaceuticals Inc.

INM
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. The company's prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. Its lead product is INM-755, a cannabinol topical skin cream, which is in Phase 2 clinical trial for the treatment of epidermolysis bullosa. The company is also developing INM-088, which is in preclinical studies for the treatment of glaucoma; INM-405 for the treatment of pain; and cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. In addition, it offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
 CEO
 WEBSITEinmedpharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES13

InMed Pharmaceuticals Inc. Frequently Asked Questions

INM is the stock ticker symbol of InMed Pharmaceuticals Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of InMed Pharmaceuticals Inc. is 3.03 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check INM's fair value in chart for subscribers.

The fair value guage provides a quick view whether INM is over valued or under valued. Whether InMed Pharmaceuticals Inc. is cheap or expensive depends on the assumptions which impact InMed Pharmaceuticals Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INM.

As of Wed Jan 28 2026, INM's PE ratio (Price to Earnings) is -0.37 and Price to Sales (PS) ratio is 0.63. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. INM PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, InMed Pharmaceuticals Inc. has provided -0.532 (multiply by 100 for percentage) rate of return.